Immune Checkpoint Inhibitor Cardiotoxicity: Contributing Factors, Appropriate Treatments, and Retreatment OptionsPremiere Date: Wednesday, December 28, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 28, 2023
|Kerry L. Reynolds, MD (Moderator)
Assistant Professor of Medicine
Harvard Medical School
Director, Severe Immunotherapy Complications (SIC) Service
Clinical Director, Inpatient Cancer Services
Massachusetts General Hospital Cancer Center
|Tomas G. Neilan, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Director, Cardio-Oncology Program
Co-Director, Cardiovascular Imaging Research Program
Massachusetts General Hospital
Immune checkpoint inhibitors (ICIs) have permanently changed the landscape of cancer therapy. However, up to half of patients who receive ICIs experience immune-related adverse events (irAEs), and some portion (1-2%, perhaps more) experience cardiotoxicity, such as myocarditis or other cardiovascular events. Recognizing ICI-related cardiotoxicity and initiating prompt treatment is critical. Whether to restart these patients on ICIs is controversial. ICI-related cardiotoxicity is rare, but clear guidelines to screen and treat CV toxicity are lacking, and clinicians need education on cardiotoxic effects of ICI therapy and guidance on rechallenging with ICI therapy.
This initiative seeks to fill those knowledge gaps among cardiologists and clinicians caring for patients with cancer who receive ICI therapy. Clinicians will receive education on the available clinical evidence to make informed decisions regarding resumption of therapy.
At the end of this CE activity, participants should be able to:
- Summarize factors contributing to cardiotoxicity associated with ICI use.
- Differentiate risk of outcome severity in patients after experiencing ICI-related cardiotoxicity.
- Select appropriate treatment approaches for ICI-related cardiotoxicity.
- Appraise current clinical evidence for and against ICI rechallenge in patients experiencing CV AEs after ICI therapy.
Supported by educational grant from Bristol Myers Squibb.
Cardiologists, oncologists, PCPs, PAs, NPs, nurses, and pharmacists.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Reynolds reports the following financial relationships:
Research Support: Project Data Sphere (a non-profit company)
Stock Shareholder (ownership interest): Biogen
Other Financial or Material Support: (ownership interest): Teledoc Health, Inc.
Dr. Neilan reports the following financial relationships:
Consultant: AbbVie Inc.; Bristol Myers Squibb; CRO Oncology; C4-Therapeutics, Inc.; Genentech, Inc.; Roche; and Sanofi
Grants: AstraZeneca and Bristol Myers Squibb
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).